A new clinical trial at HonorHealth Research Institute uses a vaccine-based on immune system dendritic cells to fight advanced melanoma. The vaccine has shown promising results in treating refractory and unresectable cases of the disease, with a 10-fold increase in immune response.
The FDA has granted early access to clinical trials for the new medication, allowing HonorHealth Research Institute to offer it to patients with previously treated metastatic pancreatic cancer. The drug has shown significant advancement in targeted therapy for pancreatic cancer, offering a median overall survival of 13.2 months.
Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.
Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.
The Restore-1 clinical trial aims to modify the small intestine's lining with steam energy to restore natural blood-sugar control in patients with type 2 diabetes. The procedure, if successful, could prevent patients from advancing to insulin-dependent diabetes.
The PerQdisc procedure, a less-invasive treatment option, preserves the outer part of the disc, maintaining mobility and restoring functionality. Dr. Luis Tumialan's first patient experienced significant pain relief and was able to resume normal activities shortly after the procedure.
Researchers created a 3D chip platform called ASTEROIDS that mimics human physiology and enables precise testing of new drugs and personalized medicine models. The technology has the potential to reduce animal testing in cancer research and improve human clinical outcomes.
A stroke patient at HonorHealth Research Institute is the first in Arizona to receive a new investigational treatment targeting platelets. BB-031 extends the treatment window and increases patients' safety. This represents a completely new approach to treating ischemic stroke.
A patient with refractory synovial sarcoma was the first in Arizona to receive TECELRA, a genetically modified autologous T cell immunotherapy. The treatment showed early signs of tumor shrinkage and has been shown to benefit over 40% of patients with similar cancer types.
Researchers at HonorHealth Research Institute have developed a new technique using ultrasound to activate targeted drugs in pancreatic cancer treatment. The Acoustic Cluster Therapy (ACT) method helps increase the effectiveness of chemotherapy while reducing potential toxicity throughout the body.
Dr. Laura Goetz will develop protocols for disease prevention across HonorHealth's research divisions, fostering strong educational and clinical bonds with students at Arizona State University's new School of Medicine. The Institute aims to create a joint program combining translational medicine innovations with clinical settings.
Dr. Schork brings expertise in human longevity and health maintenance to the Center for Translational Science. He aims to intercept disease before symptoms appear using advanced technologies such as genome monitoring and AI-powered analysis.
Researchers at HonorHealth Institute used non-surgical techniques to treat damaged heart valves, increasing survival rates for patients suffering from structural shock. The study found that 86% of patients survived at least 3 months and 73% survived at least 6 months.
The HonorHealth Research Institute's HALO program uses over 1 million variables to track brain stroke patient outcomes and guide treatment decisions. This data-driven approach has led to improved recovery rates for patients, including a high clearance rate for mechanical thrombectomy procedures.
Researchers have developed a novel combination therapy, MAG 7, comprising seven drugs to target various biologic elements in pancreatic cancer. The study aims to induce ER stress and kill cancer cells through UPR pathways.
A patient with cutaneous squamous cell carcinoma was treated with WTX-124 and achieved complete remission after 12 weeks. The investigational drug is designed to stimulate antitumor immunity with reduced toxicity, offering new hope for patients with limited treatment options.
A new study presents RMC-6236, a powerful inhibitor of RAS genes, showing promise in combination with other treatments. The study suggests that combining RMC-6236 with chemotherapy and targeted therapies could overcome therapy resistances and improve therapeutic outcomes in pancreatic cancer.
A new clinical study has treated its first patient with a novel therapy aimed at difficult-to-treat melanoma skin cancer tumors. The treatment uses modified immune-system T cells to target PRAME, a peptide found in many melanoma tumor cells.
The new laboratory complements HonorHealth's two decades of investigational therapeutics and will help take the Institute to the next level. The Center aims to translate scientific breakthroughs into new devices, drugs, and preventative measures that improve patient lives.
Dr. Sunil Sharma, a renowned expert in creating anti-cancer drugs, has been named director of HonorHealth Research Institute's new Center for Translational Science. He will lead the development of grants, education, and collaborations to translate basic scientific discoveries into advanced treatments.
Cardiac Electrophysiologist Rahul Doshi performs the nation's first procedure to control Afib using a new type of catheter that can deliver two different types of electrical energy. The new ablation system allows for precise and flexible treatment without harming healthy tissue.
Dr. Gordon was named a Fellow of the American Society of Clinical Oncology (FASCO) in recognition of his extraordinary dedication to improving cancer research and patient outcomes. He has led HonorHealth Research Institute's clinical trials programs and contributed significantly to developing new cancer treatments.
The new center aims to translate discoveries into better diagnostics and treatments, benefiting patients worldwide. HonorHealth's research institute is investing in cutting-edge clinical trials and collaborations to develop novel therapies.